In-transit melanoma metastases: Evaluation and management for the dermatologist.

In-transit metastases are estimated to occur in 5% to 10% of primary cutaneous melanomas. They are classified as stage III disease in the American Joint Committee on Cancer classification system and are associated with approximately a 30% 10-year survival rate. The management of in-transit metastases is not standardized. Treatment options depend on the number of lesions, location, distribution of in-transit metastases, and general medical condition of the patient. Topical, local, regional, and systemic treatment options can be considered for treatment. Dermatologists may play a unique role in management through skin-directed therapies.